Cue Biopharma (CUE) Competitors $0.64 0.00 (-0.52%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. NBTX, TIL, SOPH, BTMD, KOD, NVCT, INBX, PRQR, MNPR, and ELDNShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Nanobiotix (NBTX), Instil Bio (TIL), SOPHiA GENETICS (SOPH), biote (BTMD), Kodiak Sciences (KOD), Nuvectis Pharma (NVCT), Inhibrx (INBX), ProQR Therapeutics (PRQR), Monopar Therapeutics (MNPR), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors Nanobiotix Instil Bio SOPHiA GENETICS biote Kodiak Sciences Nuvectis Pharma Inhibrx ProQR Therapeutics Monopar Therapeutics Eledon Pharmaceuticals Nanobiotix (NASDAQ:NBTX) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends. Is NBTX or CUE more profitable? Nanobiotix has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Nanobiotix's return on equity of 0.00% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Cue Biopharma -468.02%-156.38%-88.07% Does the media refer more to NBTX or CUE? In the previous week, Nanobiotix had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Nanobiotix and 2 mentions for Cue Biopharma. Nanobiotix's average media sentiment score of 1.60 beat Cue Biopharma's score of 0.93 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in NBTX or CUE? Cue Biopharma received 134 more outperform votes than Nanobiotix when rated by MarketBeat users. However, 63.16% of users gave Nanobiotix an outperform vote while only 52.14% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformNanobiotixOutperform Votes1263.16% Underperform Votes736.84% Cue BiopharmaOutperform Votes14652.14% Underperform Votes13447.86% Which has more risk and volatility, NBTX or CUE? Nanobiotix has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Do analysts prefer NBTX or CUE? Nanobiotix presently has a consensus target price of $8.00, suggesting a potential upside of 38.89%. Cue Biopharma has a consensus target price of $3.00, suggesting a potential upside of 371.92%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Cue Biopharma is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in NBTX or CUE? 38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 10.8% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, NBTX or CUE? Nanobiotix has higher earnings, but lower revenue than Cue Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix-$11.61M-23.39-$42.97MN/AN/ACue Biopharma$7.99M5.99-$50.73M-$0.67-0.95 SummaryNanobiotix and Cue Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.90M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.718.6727.1419.96Price / Sales5.99262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.786.597.064.69Net Income-$50.73M$143.75M$3.23B$248.14M7 Day Performance0.89%3.72%2.67%2.39%1 Month Performance-15.35%11.01%8.82%6.05%1 Year Performance-57.62%3.87%31.44%13.60% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.4783 of 5 stars$0.64-0.5%$3.00+371.9%-56.5%$47.90M$7.99M-0.7160Gap DownNBTXNanobiotix2.8888 of 5 stars$4.13+0.8%$8.00+93.5%-12.7%$194.85M-$11.61M0.00100News CoveragePositive NewsShort Interest ↓Gap UpTILInstil Bio2.6586 of 5 stars$29.65+10.0%$112.33+278.9%+237.3%$194.47MN/A-2.56410Short Interest ↑High Trading VolumeSOPHSOPHiA GENETICS1.8285 of 5 stars$2.91-3.0%$6.80+133.7%-38.1%$194.06M$67.17M-2.67520News CoverageGap DownBTMDbiote3.726 of 5 stars$3.54+2.3%$8.00+126.0%-35.4%$193.67M$199.38M13.62194KODKodiak Sciences4.3218 of 5 stars$3.60+5.9%$9.00+150.0%+42.9%$189.95MN/A-0.9990Short Interest ↓NVCTNuvectis Pharma2.8221 of 5 stars$8.98-4.6%$17.00+89.3%+33.2%$187.63MN/A-7.748Positive NewsINBXInhibrx3.105 of 5 stars$12.96-3.8%N/A-12.8%$187.61M$200K0.11166Positive NewsUpcoming EarningsPRQRProQR Therapeutics3.0236 of 5 stars$1.78+7.2%$8.00+349.4%-0.5%$187.28M$18.97M-5.56180Positive NewsAnalyst RevisionMNPRMonopar Therapeutics3.252 of 5 stars$30.01-5.4%$55.33+84.4%+750.4%$183.51MN/A-15.2310News CoveragePositive NewsELDNEledon Pharmaceuticals2.624 of 5 stars$3.06+2.0%$12.50+308.5%+3.4%$183.24MN/A-1.5210Gap Up Related Companies and Tools Related Companies Nanobiotix Alternatives Instil Bio Alternatives SOPHiA GENETICS Alternatives biote Alternatives Kodiak Sciences Alternatives Nuvectis Pharma Alternatives Inhibrx Alternatives ProQR Therapeutics Alternatives Monopar Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
